Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 225

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

DNA methylation profiling reveals a predominant immune component in breast cancers

Open access
Dedeurwaerder, Sarah, Desmedt, Christine, Calonne, Emilie, Singhal, Sandeep K., Haibe‐Kains, Benjamin, Defrance, Matthieu, Michiels, Stefan, Volkmar, Michael, Deplus, Rachel, Luciani, Judith, Lallemand, Françoise, Larsimont, Denis, Toussaint, Jérôme, Haussy, Sandy, Rothé, Françoise, Rouas, Ghizlane, Metzger, Otto, Majjaj, Samira, Saini, Kamal, Putmans, Pascale, Hames, Gérald, van Baren, Nicolas, Coulie, Pierre G., Piccart, Martine, Sotiriou, Christos, Fuks, François·2011·EMBO Molecular Medicine

Abstract

Breast cancer is a molecularly, biologically and clinically heterogeneous group of disorders. Understanding this diversity is essential to improving diagnosis and optimizing treatment. Both genetic and acquired epigenetic abnormalities participate in cancer, but the involvement of the epigenome in breast cancer and its contribution to the complexity of the disease are still poorly understood. By means of DNA methylation profiling of 248 breast tissues, we have highlighted the existence of previously unrecognized breast cancer groups that go beyond the currently known ‘expression subtypes’. Interestingly, we showed that DNA methylation profiling can reflect the cell type composition of the tumour microenvironment, and in particular a T lymphocyte infiltration of the tumours. Further, we highlighted a set of immune genes having high prognostic value in specific tumour categories. The immune component uncovered here by DNA methylation profiles provides a new perspective for the importance of the microenvironment in breast cancer, holding implications for better management of breast cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/emmm.201100801

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 225

Metadata

Authors
Dedeurwaerder, S., Desmedt, C., Calonne, E., Singhal, S. K., Haibe‐Kains, B., Defrance, M., Michiels, S., Volkmar, M., Deplus, R., Luciani, J., Lallemand, F., Larsimont, D., Toussaint, J., Haussy, S., Rothé, F., Rouas, G., Metzger, O., Majjaj, S., Saini, K., Putmans, P., Hames, G., van Baren, N., Coulie, P. G., Piccart, M., Sotiriou, C., & Fuks, F.
Venue
EMBO Molecular Medicine
Published
2011-11-16
Volume
3
Issue
12
Pages
726-741
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2134345937
Cited by
225
References
3
FWCI
6.35
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DNA methylation profiling reveals a predominant immune component in breast cancers. https://app.cochat.ai/papers/10.1002/emmm.201100801
The paper
Dedeurwaerder, S., Desmedt, C., Calonne, E., Singhal, S. K., Haibe‐Kains, B., Defrance, M., Michiels, S., Volkmar, M., Deplus, R., Luciani, J., Lallemand, F., Larsimont, D., Toussaint, J., Haussy, S., Rothé, F., Rouas, G., Metzger, O., Majjaj, S., Saini, K., . . . Fuks, F. (2011). DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Molecular Medicine. https://doi.org/10.1002/emmm.201100801

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.